Indeed, data obtained in other solid tumors showed that inhibition of both mTOR signaling and Bcl-2 family activity did trigger in vivo tumor regressions (Preuss et al., 2013; Jebahi et al., 2014; Iacovelli et al., 2015; Li et al., 2017). The gene discussed is MTOR; the disease is neoplasm.